903550-12-9

Usage

Uses

Used in Medicinal Chemistry and Drug Discovery:
1-(2-Trimethylsilanylethoxymethyl)-1H-pyrazole-5-boronic acid pinacol ester is used as a building block for the development of new pharmaceuticals due to its ability to form stable complexes with certain biomolecules and enzymes. This property is crucial for the discovery of potential drug candidates that can modulate biological targets effectively.
Used in Advanced Materials Development:
In the field of materials science, 1-(2-Trimethylsilanylethoxymethyl)-1H-pyrazole-5-boronic acid pinacol ester is used as a component in the synthesis of advanced materials. Its unique chemical structure allows for the creation of materials with specific properties, such as improved stability or reactivity, which can be tailored for various applications.
Used in Chemical Processes:
1-(2-Trimethylsilanylethoxymethyl)-1H-pyrazole-5-boronic acid pinacol ester is employed as a reagent in various chemical processes. The trimethylsilyl group enhances the stability of the boronic acid functionality, making it suitable for use in reactions that require a protected boronic acid intermediate, thus facilitating the synthesis of complex organic compounds.

InChI:InChI=1/C15H29BN2O3Si/c1-14(2)15(3,4)21-16(20-14)13-8-9-17-18(13)12-19-10-11-22(5,6)7/h8-9H,10-12H2,1-7H3

Upstream product

• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 133560-57-3 1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-pyrazole 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 844501-71-9 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole 

Downstream Products

• 903550-15-2 5-(2-bromo-phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazole 
• 903550-17-4 2-[2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyrazol-3-yl]-benzoic acid methyl ester 
• 903550-16-3 2-[2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyrazol-3-yl]-benzaldehyde 
• 903550-14-1 2-[2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyrazol-3-yl]-benzonitrile 
• 903550-18-5 2-[2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyrazol-3-yl]-benzoic acid ethyl ester 
• 903550-19-6 4-[2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyrazol-3-yl]-benzoic acid methyl ester 
• 1319158-66-1 4-(3,4-dichlorophenyl)-6-[2-(2-trimethylsilanylethoxymethyl)-2H-pyrazol-3-yl]pyrimidine 
• 1541188-74-2 (6-{4-[2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyrazol-3-yl]-phenoxy}-imidazo[1,2-a]pyridin-2-yl)-methanol 
• 1541188-73-1 C₂₅H₃₀N₄O₄Si 
• 1541188-29-7 5-[4-[2-(2-trimethylsilylethoxymethyl)pyrazol-3-yl]phenoxy]pyridin-2-amine 
• 1419211-50-9 4-[2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyrazol-3-yl]-phenol 
• 1541188-97-9 C₂₇H₃₅N₅O₃Si 
• 1541188-96-8 C₂₄H₃₀N₄O₅SSi 
• 1541188-95-7 C₂₃H₂₈N₄O₃Si 

Relevant academic research and scientific papers

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

Efficient and simple synthesis of 3-aryl-1H-pyrazoles

Efficient preparation of 3-aryl-1H-pyrazoles by reaction of 1-protected-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazoles with (het)aryl halides is described. The choice of THP protecting group is discussed.